enGene to Participate in Upcoming Investor Conferences
enGene Holdings Inc. (Nasdaq: ENGN), a clinical-stage genetic medicines company, announced its participation in three upcoming investor conferences in September 2024. The company's lead program, detalimogene voraplasmid, is currently in a pivotal study for high-risk, BCG-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis).
The conferences include:
- Morgan Stanley 22nd Annual Healthcare Conference on September 5
- Wells Fargo Healthcare Conference on September 6
- H.C. Wainwright 26th Annual Global Investment Conference on September 11
Presentations will be given by Ron Cooper (CEO), Raj Pruthi (CMO), and Alex Nichols (COO). Live webcasts will be available on the enGene website for 90 days after each event.
enGene Holdings Inc. (Nasdaq: ENGN), un'azienda di medicina genetica in fase clinica, ha annunciato la sua partecipazione a tre prossime conferenze per investitori a settembre 2024. Il programma principale dell'azienda, detalimogene voraplasmid, è attualmente in uno studio pivotale per il tumore della vescica non muscolo invasivo (NMIBC) ad alto rischio, non reattivo al BCG, con carcinoma in situ (Cis).
Le conferenze includono:
- La 22a Conferenza Annuale sulla Salute di Morgan Stanley il 5 settembre
- La Conferenza Sanitaria di Wells Fargo il 6 settembre
- La 26a Conferenza Globale Annuale sugli Investimenti di H.C. Wainwright l'11 settembre
Le presentazioni saranno effettuate da Ron Cooper (CEO), Raj Pruthi (CMO) e Alex Nichols (COO). Le webcast in diretta saranno disponibili sul sito web di enGene per 90 giorni dopo ciascun evento.
enGene Holdings Inc. (Nasdaq: ENGN), una empresa de medicamentos genéticos en etapa clínica, anunció su participación en tres próximas conferencias para inversores en septiembre de 2024. El programa principal de la empresa, detalimogene voraplasmid, se encuentra actualmente en un estudio pivotal para cáncer de vejiga no musculoesquelético (NMIBC) de alto riesgo, no sensible al BCG, con carcinoma in situ (Cis).
Las conferencias incluyen:
- La 22ª Conferencia Anual de Salud de Morgan Stanley el 5 de septiembre
- La Conferencia de Salud de Wells Fargo el 6 de septiembre
- La 26ª Conferencia Global Anual de Inversiones de H.C. Wainwright el 11 de septiembre
Las presentaciones estarán a cargo de Ron Cooper (CEO), Raj Pruthi (CMO) y Alex Nichols (COO). Las transmisiones en vivo estarán disponibles en el sitio web de enGene durante 90 días después de cada evento.
enGene Holdings Inc. (Nasdaq: ENGN), 임상 단계의 유전자 의약품 회사는 2024년 9월에 다가오는 세 가지 투자자 회의에 참여한다고 발표했습니다. 회사의 주요 프로그램인 detalimogene voraplasmid는 고위험 BCG 비반응성 비근육 침습성 방광암(NMIBC) 및 제자리암(Cis)에 대한 주요 연구에 있습니다.
회의 일정은 다음과 같습니다:
- 모건 스탠리 제22회 연례 헬스케어 컨퍼런스 9월 5일
- 웰스 파고 헬스케어 컨퍼런스 9월 6일
- H.C. 웨인라이트 제26회 글로벌 투자 컨퍼런스 9월 11일
발표자는 Ron Cooper (CEO), Raj Pruthi (CMO), Alex Nichols (COO)입니다. 각 이벤트 후 90일 동안 enGene 웹사이트에서 라이브 웹캐스트를 확인할 수 있습니다.
enGene Holdings Inc. (Nasdaq: ENGN), une entreprise de médicaments génétiques en phase clinique, a annoncé sa participation à trois conférences d'investisseurs à venir en septembre 2024. Le programme phare de l'entreprise, detalimogene voraplasmid, est actuellement dans une étude pivot pour le cancer de la vessie non invasif musculaire à haut risque, non réactif au BCG, avec carcinome in situ (Cis).
Les conférences incluent :
- 22ème Conférence Annuelle sur la Santé de Morgan Stanley le 5 septembre
- Conférence sur la santé de Wells Fargo le 6 septembre
- 26ème Conférence Annuelle Mondiale d'Investissement de H.C. Wainwright le 11 septembre
Les présentations seront faites par Ron Cooper (CEO), Raj Pruthi (CMO) et Alex Nichols (COO). Les webcasts en direct seront disponibles sur le site d'enGene pendant 90 jours après chaque événement.
enGene Holdings Inc. (Nasdaq: ENGN), ein Unternehmen für genetische Medikamente in der klinischen Phase, gab seine Teilnahme an drei bevorstehenden Investorenkonferenzen im September 2024 bekannt. Das Hauptprogramm des Unternehmens, detalimogene voraplasmid, befindet sich derzeit in einer entscheidenden Studie für hochrisikobehafteten, BCG-reaktiven, nicht muskelinvasiven Blasen-Krebs (NMIBC) mit Carcinoma in situ (Cis).
Die Konferenzen umfassen:
- 22. Annual Healthcare Conference von Morgan Stanley am 5. September
- Wells Fargo Healthcare Conference am 6. September
- 26. Annual Global Investment Conference von H.C. Wainwright am 11. September
Präsentationen werden von Ron Cooper (CEO), Raj Pruthi (CMO) und Alex Nichols (COO) gehalten. Live-Webcasts werden 90 Tage nach jeder Veranstaltung auf der Webseite von enGene verfügbar sein.
- None.
- None.
Details of the conferences are below:
Conference: Morgan Stanley 22nd Annual Healthcare Conference
Date: Thursday, September 5, 2024
Time: 4:50 p.m. ET
Location:
Format: Fireside Chat
Presenters: Ron Cooper, Chief Executive Officer; Raj Pruthi, Chief Medical Officer
Conference: Wells Fargo Healthcare Conference
Date: Friday, September 6, 2024
Time: 11:00 a.m. ET
Location:
Format: Corporate Presentation
Presenter: Ron Cooper, Chief Executive Officer
Conference: H.C. Wainwright 26th Annual Global Investment Conference
Date: Wednesday, September 11, 2024
Time: 9:30 a.m. ET
Location:
Format: Corporate Presentation
Presenter: Alex Nichols, Chief Operating Officer
A live webcast of each of these presentations can be accessed under the Investors section of the enGene website at https://engene.com/presentations/ and will be archived there for 90 days.
About enGene
enGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene’s lead program is detalimogene voraplasmid (previously known as EG-70) for patients with non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG) – a disease with a high clinical burden. Detalimogene voraplasmid is being evaluated in an ongoing Phase 2 pivotal study. Detalimogene voraplasmid was developed using enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA. For more information, visit enGene.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828277262/en/
Investor Contact
investors@engene.com
Media Contact
media@engene.com
Source: enGene Holdings Inc.
FAQ
What investor conferences will enGene (ENGN) attend in September 2024?
What is enGene's (ENGN) lead program and its current stage of development?
Who will be presenting on behalf of enGene (ENGN) at these investor conferences?
How can investors access the presentations from enGene's (ENGN) conference appearances?
